Kristof Raemdonck
Overview
Explore the profile of Kristof Raemdonck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodrigues J, Rocha M, Teixeira F, Resende B, Cardoso A, Sa S, et al.
Physiol Behav
. 2023 Mar;
265:114171.
PMID: 36965572
Background: Allergic rhinitis (AR) has been identified as a cause of olfactory dysfunction. Beyond the classic symptoms, AR has been associated with altered sleep patterns, a decline in cognitive performance...
2.
Rodrigues J, Pinto J, Alexandre P, Sousa-Pinto B, Pereira A, Raemdonck K, et al.
Laryngoscope
. 2022 Aug;
133(6):1321-1327.
PMID: 35912902
Objectives: Allergic rhinitis (AR) has been associated with anxiety and depression. A possible influence of frequency and intensity of the AR symptoms has remained unclear. Therefore, we evaluated the association...
3.
Belvisi M, Baker K, Malloy N, Raemdonck K, Dekkak B, Pieper M, et al.
Respir Res
. 2018 May;
19(1):89.
PMID: 29747661
Background: Asthmatics that are exposed to inhaled pollutants such as cigarette smoke (CS) have increased symptom severity. Approximately 25% of adult asthmatics are thought to be active smokers and many...
4.
Baker K, Raemdonck K, Snelgrove R, Belvisi M, Birrell M
Respir Res
. 2017 Apr;
18(1):55.
PMID: 28399855
Background: The incidence of asthma is increasing at an alarming rate. While the current available therapies are effective, there are associated side effects and they fail to adequately control symptoms...
5.
Baker K, Raemdonck K, Dekkak B, Snelgrove R, Ford J, Shala F, et al.
Respir Res
. 2016 Jun;
17(1):67.
PMID: 27255083
Background: Asthma prevalence has increased world-wide especially in children; thus there is a need to develop new therapies that are safe and effective especially for patients with severe/refractory asthma. CD4(+)...
6.
Raemdonck K, Baker K, Dale N, Dubuis E, Shala F, Belvisi M, et al.
Respir Res
. 2016 Apr;
17:45.
PMID: 27112462
Background: The incidence of asthma is increasing at an alarming rate and while the current available therapies are effective in the majority of patients they fail to adequately control symptoms...
7.
Kaur M, Birrell M, Dekkak B, Reynolds S, Wong S, De Alba J, et al.
Pulm Pharmacol Ther
. 2015 Sep;
35:67-74.
PMID: 26344428
Asthma is increasing globally and current treatments only manage a proportion of patients. There is an urgent need to develop new therapies. Lymphocytes are thought to play a central role...
8.
Birrell M, Bonvini S, Dubuis E, Maher S, Wortley M, Grace M, et al.
J Allergy Clin Immunol
. 2014 Feb;
133(3):679-87.e9.
PMID: 24506933
Background: Recent studies have suggested that the long-acting muscarinic receptor antagonist tiotropium, a drug widely prescribed for its bronchodilator activity in patients with chronic obstructive pulmonary disease and asthma, improves...
9.
Birrell M, Maher S, Buckley J, Dale N, Bonvini S, Raemdonck K, et al.
Br J Pharmacol
. 2012 Jul;
168(1):129-38.
PMID: 22747912
Background And Purpose: Understanding the role of the EP(2) receptor has been hampered by the lack of a selective antagonist. Recently, a selective EP(2) receptor antagonist, PF-04418948, has been discovered....
10.
Eltom S, Stevenson C, Rastrick J, Dale N, Raemdonck K, Wong S, et al.
PLoS One
. 2011 Sep;
6(9):e24097.
PMID: 21915284
Chronic Obstructive Pulmonary Disease (COPD) is a cigarette smoke (CS)-driven inflammatory airway disease with an increasing global prevalence. Currently there is no effective medication to stop the relentless progression of...